Profile data is unavailable for this security.
About the company
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company’s main shareholders are Biofol AB and Yield Life Science AB.
- Revenue in SEK (TTM)0.00
- Net income in SEK-54.49m
- Incorporated2008
- Employees6.00
- LocationIsofol Medical AB (publ)Biotech Center, Arvid Wallgrens Backe 20GOETEBORG 413 46SwedenSWE
- Phone+46 317972280
- Fax+46 317411701
- Websitehttps://isofolmedical.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pila Pharma AB | 957.89k | -11.26m | 50.75m | 0.00 | -- | 31.64 | -- | 52.99 | -0.3702 | -0.3702 | 0.0315 | 0.0381 | 0.2406 | -- | 7.20 | -- | -282.78 | -113.42 | -602.96 | -128.21 | -679.51 | -118.10 | -1,175.22 | -1,491.09 | -- | -136.10 | 0.00 | -- | -47.03 | 17.47 | -13.21 | -- | -- | -- |
| ExpreS2ion Biotech Holding AB | 10.85m | -45.17m | 54.65m | 20.00 | -- | 1.24 | -- | 5.04 | -44.22 | -44.22 | 5.14 | 12.52 | 0.1305 | -- | 5.67 | 571,157.90 | -54.33 | -58.63 | -85.25 | -70.70 | 55.64 | -18.17 | -416.26 | -621.40 | -- | -- | 0.0433 | -- | -11.07 | -10.76 | 60.57 | -- | 5.08 | -- |
| XP Chemistries AB | 311.47k | -7.67m | 58.40m | 2.00 | -- | 1.48 | -- | 187.50 | -0.042 | -0.042 | 0.0017 | 0.126 | 0.0095 | 3.58 | 9.76 | 155,735.00 | -23.42 | -- | -25.03 | -- | -1,850.65 | -- | -2,461.64 | -- | 17.17 | -- | 0.00 | -- | -57.22 | -- | 11.26 | -- | -- | -- |
| Odi Pharma AB (publ) | 8.97m | -4.72m | 68.56m | 1.00 | -- | 234.35 | -- | 7.64 | -0.2851 | -0.2851 | 0.5266 | 0.016 | 1.33 | -- | 5.29 | 8,971,460.00 | -70.09 | -40.68 | -1,151.76 | -60.97 | -29.08 | -- | -52.61 | -95.17 | -- | -8.51 | 0.00 | -- | -85.94 | -- | -944.49 | -- | -- | -- |
| Oncozenge AB | 2.71m | -8.56m | 70.57m | 1.00 | -- | 7.59 | -- | 26.01 | -0.7136 | -0.7136 | 0.2282 | 0.7357 | 0.162 | -- | 3.75 | 2,713,000.00 | -51.09 | -- | -58.48 | -- | -- | -- | -315.33 | -- | -- | -610.07 | 0.4463 | -- | -- | -- | 45.37 | -- | -- | -- |
| Enorama Pharma AB | 3.82m | -76.57m | 71.75m | 5.00 | -- | -- | -- | 18.77 | -1.23 | -1.23 | 0.0595 | -0.0623 | 0.1413 | 2.71 | 2.45 | 764,600.00 | -283.01 | -88.96 | -526.84 | -127.92 | -302.88 | 15.72 | -2,002.90 | -488.89 | 0.5223 | -12.77 | -- | -- | 1,061.12 | 15.68 | 1.81 | -- | -- | -- |
| StenoCare A/S | 8.10m | -35.08m | 85.18m | 8.00 | -- | 24.06 | -- | 10.52 | -0.8176 | -0.8176 | 0.1569 | 0.0572 | 0.324 | -- | 3.80 | 709,217.50 | -140.37 | -45.69 | -201.07 | -59.64 | -- | -- | -433.19 | -739.04 | 1.32 | -6.51 | 0.526 | -- | -40.60 | -14.70 | -96.30 | -- | -64.95 | -- |
| Arctic Bioscience AS | 40.94m | -40.38m | 86.59m | 22.00 | -- | 0.4745 | -- | 2.12 | -1.67 | -1.67 | 1.69 | 7.27 | 0.156 | 0.9957 | 4.02 | 1,998,510.00 | -15.39 | -15.49 | -18.84 | -17.83 | 28.45 | 28.52 | -98.62 | -125.49 | 0.3389 | -9.68 | 0.2202 | -- | 28.84 | 7.68 | -5.31 | -- | -- | -- |
| Vivesto AB | 0.00 | -35.72m | 92.97m | 4.00 | -- | 0.348 | -- | -- | -0.0664 | -0.0664 | 0.00 | 0.2483 | 0.00 | -- | -- | 0.00 | -21.35 | -- | -23.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.12 | -- | -- | -- |
| IRLAB Therapeutics AB | 85.56m | -91.91m | 142.22m | 31.00 | -- | 2.63 | -- | 1.66 | -1.56 | -1.56 | 1.40 | 0.6382 | 0.5172 | -- | 8.93 | 3,168,815.00 | -55.56 | -27.34 | -149.51 | -32.01 | -35.80 | -45.70 | -107.43 | -112.19 | -- | -4.29 | 0.3548 | -- | 1,566.57 | 415.48 | 53.26 | -- | 7.75 | -- |
| Isofol Medical AB (publ) | 0.00 | -54.49m | 168.52m | 6.00 | -- | 1.40 | -- | -- | -0.2698 | -0.2698 | 0.00 | 0.4291 | 0.00 | -- | -- | 0.00 | -43.21 | -61.58 | -51.19 | -82.71 | -- | -740.36 | -- | -861.94 | -- | -- | 0.00 | -- | -100.00 | -- | -17.31 | -- | -- | -- |
| Magle Chemoswed Holding AB | 292.44m | -26.60m | 241.60m | 144.00 | -- | 0.4543 | 8.72 | 0.8262 | -1.29 | -1.29 | 14.56 | 25.75 | 0.3085 | -0.0596 | 8.14 | 1,989,374.00 | -2.81 | 2.43 | -3.45 | 3.45 | 102.66 | 88.63 | -9.09 | 4.76 | 0.8205 | -0.1043 | 0.3887 | 0.00 | 38.49 | 13.10 | -1.91 | 74.06 | -21.72 | -- |
Data as of Feb 09 2026. Currency figures normalised to Isofol Medical AB (publ)'s reporting currency: Swedish Krona SEK
1.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Dec 2025 | 1.74m | 0.62% |
| SEB Funds ABas of 31 Dec 2025 | 1.70m | 0.61% |
| Skandia Investment Management ABas of 28 Nov 2025 | 341.37k | 0.12% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 30.02k | 0.01% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
